JCI Insight Submission Process

First decisions on direct submissions are weighted toward the editorial-board desk screen. For papers sent to referees, the journal reports an average time to decision of about 21 days, with SciRev showing roughly 1.1 months for a first review round, while edge cases diverge sharply: an immediate desk rejection is an expedited outcome in about 6 days, a JCI transfer is an outlier that can decide in fewer than 7 days, and a standard accepted paper can run 113 to 132 days through revision. JCI Insight is the clinically-relevant sibling of JCI, and the route into the journal is the dominant feature of the early timeline.

If you want an outside read before you open the portal, use the free manuscript readiness check to test whether the disease relevance survives a fast editorial-board screen.

Initial quality check: completeness and policy fit

The first layer is administrative but still decisive. Before the board reads for relevance, the intake verifies authorship and the all-author approval step JCI Insight requires for revised submissions, competing-interest declarations, ethics and consent statements for human or animal work, a plagiarism and similarity scan, and a data-availability statement. A submission can look finished in the portal and still be weak if the abstract and first figure do not make the disease relevance and the translational link obvious.

Editorial assignment: routing by disease relevance

JCI Insight is screened by an editorial board of practicing physician-scientists, so the decision-making style emphasizes whether the work advances understanding or treatment of disease, not only whether the experiments are clean. The disease question you signal in the title and abstract determines how the board reads the contribution, and a basic-science framing can make a translationally relevant study read as out of scope.

Peer review: disease-relevance assessment after the desk screen

Manuscripts that clear the desk screen move to at least two, often three, expert referees under single-blind review. The referee job is not only to check that the methods are sound. It is to decide whether the disease relevance is real, whether the translational or clinical link is supported, and whether the advance is meaningful for the field, with referees also assigning a priority based on content, quality, and relevance.

Final decision: relevance stays live after reports return

Even after review, the decision still turns on disease relevance and significance. A technically clean paper can be returned if the reports show the clinical or translational link is thin, the advance is incremental, or the work fits a specialty journal better than a broad clinically-relevant venue.

This is where the fast first decision on direct submissions comes from. Before any referee is assigned, the editorial board reads the abstract, the central disease question, and the significance claim, and decides whether the paper is a credible, clinically-relevant advance in scope for JCI Insight.

At this stage the board is effectively asking:

• does this study advance understanding or treatment of a disease, or is it basic science with the disease link asserted late?

• is the translational or clinical relevance strong enough for JCI Insight rather than a specialty journal?

• is the package complete, with ethics statements, data availability, and all-author approvals in place?

Because this screen is fast, an immediate decision on a direct submission, commonly in about 6 days, is almost always a desk return rather than an acceptance. A sub-7-day decision on a transferred manuscript is a different signal entirely.

Papers that pass triage go to at least two, often three, referees, who typically assess:

• disease relevance and the strength of the translational or clinical link

• rigor, reproducibility, and the adequacy of controls

• whether the advance is meaningful for understanding or treating disease

• whether the conclusions are supported by the data and appropriately bounded

• clarity of the disease question in the abstract and figures

JCI Insight uses single-blind peer review, so referees see author identities while staying anonymous themselves, and the dual-submission and JCI transfer route means a manuscript reviewed at JCI can be moved to JCI Insight with its reviews intact. Reviewed-manuscript decisions average about 21 days on the journal's own figure, though a single manuscript can move faster or slower depending on referee availability and the route into the journal.

• Reject (fast, pre-review): a desk return from the editorial board, usually on disease relevance, significance, or scope. Re-route to a specialty journal or sharpen the translational framing before resubmitting elsewhere.

• Transfer offer: the board judges the work better suited to JCI Insight than JCI, or vice versa; accepting carries your reviews and is usually the fastest path to a decision.

• Major revision: substantive referee concerns, often about the strength of the translational claim, rigor, or whether the advance is meaningful. The revised paper usually returns to the same referees; respond point by point.

• Minor revision: the paper is essentially accepted pending specific fixes. Respond carefully and promptly.

• Accept: uncommon on the first round; usually follows a clean revision.

Four recurring patterns return otherwise-capable JCI Insight packages in the first decision window:

• Reading the wrong clock. A sub-7-day decision on a transfer is not a desk rejection, and a 6-day decision on a direct submission is not a fast acceptance. Confusing the two leads authors to give up or celebrate at the wrong moment.
• Asserting disease relevance instead of showing it. A basic-science study that reaches the disease connection only in the discussion reads to the editorial board as out of scope. The desk screen wants the translational link in the abstract and first figure.
• Incremental advance for a broad clinically-relevant venue. A solid but narrow result that does not change understanding or treatment is what the board returns first; a specialty journal is often the better home.
• Incomplete ethics, data, or approval signals. Missing consent or animal-ethics statements, a vague data-availability line, or absent all-author approvals on a revision are avoidable pre-review returns.

Check whether your JCI Insight abstract makes the disease relevance visible to the editorial board →

Check if your JCI Insight translational claim is supported before the editorial screen →

Check whether your manuscript fits JCI, JCI Insight, or a specialty journal →

This guide tells you what JCI Insight editors look for in the first decision window; the review tells you whether your paper passes that screen. 60-day money-back guarantee; authors retain all rights and we do not train models on submitted manuscripts.

In our pre-submission review work on JCI Insight submissions, three patterns account for most of the manuscripts that stall in the fast first-decision window, before a referee is ever assigned.

The disease relevance is asserted, not shown

We repeatedly see JCI Insight manuscripts where the abstract and introduction open with mechanism and only reach the disease connection in the final paragraph of the discussion. Because the editorial-board desk screen reads the abstract, the central disease question, and the first figure, a translational link that surfaces late reads as basic science in search of a clinical frame. The fix we push is to make the disease relevance and the translational claim legible in the first three sentences and in the first figure.

The route into the journal is misread

A related pattern is an author who treats every fast decision the same way. A sub-7-day decision on a JCI transfer reflects carried-over reviews and is often an opportunity, while a 6-day decision on a direct submission is a desk return. We help authors read the portal status against the route they took, so a transfer offer is not declined out of confusion and a desk return is not mistaken for bad luck. The portal status, the abstract, and the cover letter together tell you which clock you are on, and reading them against your submission route is the JCI Insight skill that prevents a costly misread.

The advance is incremental for a broad clinically-relevant venue

The third pattern is a clean but narrow study that does not change understanding or treatment of disease, framed for a broad audience. The physician-scientist board registers an incremental advance immediately, and it reframes a competent study as specialty work. We push authors to state plainly what the work changes about a disease and to position it against current clinically-relevant work, because that is the difference the board is screening for in the first read. In practice that means putting the disease-changing claim and the supporting results into the abstract and the first figure, the two components the JCI Insight board reads before anything else.

JCI Insight (JIF 6.1, gold open access, clinically-relevant basic and translational research) sits next to JCI and the specialty journals, and the desk screen is partly a routing decision:

• choose JCI when the advance is a major, high-impact clinical or translational finding that meets the flagship bar

• stay with JCI Insight when the work is a solid, clinically-relevant basic or translational study across any biomedical specialty

• consider a specialty journal when the contribution is narrow to one field and the broad disease relevance is limited

• use the dual-submission option when you want both JCI and JCI Insight to consider the work and let the editors route it

Last verified June 2026 against JCI Insight's public author materials, the insight.jci.org portal, and current SciRev timing data. Editorial timing varies sharply between direct submissions, transfers, and accepted paths; treat the numbers as planning ranges and confirm current figures before you submit.